Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Chemical Synapses01:26

Chemical Synapses

12.3K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.3K
Chemical Synapses01:26

Chemical Synapses

6.8K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
6.8K
Muscle Contraction01:10

Muscle Contraction

9.2K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Zhu et al.: Implications of <i>CHRNB1</i> and <i>ERBB2</i> in the pathobiology of myasthenia gravis.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America.

BMJ open·2020
Same author

Comment: Methotrexate for patients with generalized myasthenia gravis.

Neurology·2016
Same author

Treatment for Refractory Myasthenia Gravis-New Lymphs for Old.

JAMA neurology·2016
Same author

Author response.

Neurology·2015
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: Mar 14, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K

Myasthenia Gravis.

Daniel B Drachman1

  • 1Department of Neurology & Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland.

Seminars in Neurology
|October 6, 2016
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) involves reduced acetylcholine receptors (AChRs) due to autoantibodies, causing muscle weakness. Effective treatments include medications and immunotherapy, allowing most patients to live normal lives with ongoing management.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.9K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 14, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.9K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.9K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.8K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder characterized by reduced acetylcholine receptors (AChRs) at the neuromuscular junction.
  • Autoantibodies against AChRs or associated proteins (MuSK, LRP-4, agrin) cause muscle weakness and fatigue.
  • Early diagnosis of MG relies on clinical presentation, autoantibody testing, and electrophysiological studies.

Purpose of the Study:

  • To provide a comprehensive overview of the pathophysiology, diagnosis, and treatment of myasthenia gravis.
  • To highlight the importance of tailored therapeutic strategies for managing MG symptoms.
  • To emphasize the role of physician expertise in optimizing treatment outcomes and minimizing adverse effects.

Main Methods:

  • Review of current literature on myasthenia gravis.
  • Analysis of diagnostic approaches including clinical assessment, serological tests, and electrophysiology.
  • Evaluation of various therapeutic interventions, including symptomatic, immunomodulatory, and surgical options.

Main Results:

  • MG pathophysiology involves autoimmune attack on neuromuscular junctions, leading to reduced AChR function.
  • Diagnosis requires a combination of clinical, serological, and electrophysiological findings.
  • Treatment strategies encompass symptomatic relief (anticholinesterase drugs), rapid symptom reduction (IVIg, plasma exchange), intermediate-term immunotherapy (corticosteroids, calcineurin inhibitors, rituximab), and long-term maintenance (azathioprine, mycophenolate).
  • Thymectomy offers potential long-term benefits for some patients.

Conclusions:

  • Most myasthenia gravis patients can achieve normal lives with appropriate, lifelong management.
  • Effective MG treatment necessitates skilled application of immunotherapeutic agents and careful monitoring for side effects.
  • Personalized treatment plans are crucial for optimizing clinical outcomes and quality of life in MG patients.